TAILIEUCHUNG - Study on changes of plasma cell free DNA of epstein Barr virus during chemoradiotherapy of nasopharyngeal carcinoma patients

Objectives: To study fluctuation of plasma cell-free Epstein Barr virus DNA at pre-, mid- and post-radiotherapy of nasopharyngeal carcinoma patients. Methods: 21 nasopharyngeal carcinoma patients of stages I - IVB were followed up and the sensitive realtime PCR assay with detection limit of 25 copies/mL was performed for quantification of plasma cell-free Epstein Barr virus DNA. | Journal of military pharmaco-medicine no1-2019 STUDY ON CHANGES OF PLASMA CELL-FREE DNA OF EPSTEIN-BARR VIRUS DURING CHEMORADIOTHERAPY OF NASOPHARYNGEAL CARCINOMA PATIENTS Pham Quynh Huong1; Vu Nguyen Quynh Anh1; Nguyen Dinh Ung1; Bui Tien Sy2 Ngo Thanh Tung3; Le Minh Ky4; Duong Thuy Linh5; Nguyen Van Ba5 Do Tram Anh5; Ho Anh Son1; Hoang Van Luong1; Nghiem Duc Thuan5; Ho Huu Tho1 SUMMARY Objectives: To study fluctuation of plasma cell-free Epstein Barr virus DNA at pre-, mid- and post-radiotherapy of nasopharyngeal carcinoma patients. Methods: 21 nasopharyngeal carcinoma patients of stages I - IVB were followed up and the sensitive realtime PCR assay with detection limit of 25 copies/mL was performed for quantification of plasma cell-free Epstein Barr virus DNA. Results: Before radiotherapy, there were of nasopharyngeal carcinoma patients with cell-free Epstein Barr virus DNA ≥ 300 copies/mL and of nasopharyngeal carcinoma patients with detectable cell-free Epstein Barr virus DNA of less than 300 copies/ml. After radiotherapy, these numbers were 0% and . Patients with undetectable cell-free Epstein Barr virus DNA after radiotherapy accounted for , which was statistically different from before radiotherapy. Data of nasopharyngeal carcinoma patients from the middle of therapy was collected after 15 - 20 fractions. Conclusion: Changes of plasma cell-free Epstein Barr virus DNA, detected by our sensitive realtime PCR assay, represent a valuable biomarker for monitoring the response of nasopharyngeal carcinoma patients to radiotherapy. * Keywords: Nasopharyngeal carcinoma; Cell-free Epstein Barr virus; DNA; Chemoradiotherapy. INTRODUCTION Nasopharyngeal carcinoma (NPC) is malignant tumors that arise from epithelium cells of the nasopharynx - the upper part of the throat that is situated behind the nasal cavity and near the base of skull. This cancer represents a significant disease burden in Southern China and also has an .

• Y khoa - Dược
• Nasopharyngeal carcinoma patients
• Cell free Epstein Barr virus
• Plasma cell free DNA
• Sensitive realtime PCR
• Cancer tumor node metastasis
• BMC Cancer
• Nasopharyngeal carcinoma
• Cumulative dose
• High cumulative doses
• Non metastatic nasopharyngeal carcinoma
• Cisplatin related toxicities
• EBNA 1
• Vietnamese population
• Epstein Barr virus nuclear antigen 1
• Gene prevalence
• Nasopharyngeal cancer
• Staging system
• Intensity modulated radiation therapy
• Induction chemotherapy
• Concurrent chemoradiotherapy
• Randomized controlled clinical trials
• Serum miRNA
• Intensity modulated radiotherapy
• Locally advanced nasopharyngeal carcinoma
• EGFR monoclonal antibody
• Induction therapy
• Curative effect
• Adverse reaction
• EBV DNA
• Prognostic value
• Standard uptake values
• Positron emission tomography
• Locoregional recurrence
• Distant failure
• Early screening
• Epstein Barr virus
• Capsid antigen specific IgA
• Quality of life
• Prognostic factor
• Neck muscle spasm
• Dose tolerance
• Lymph node metastasis
• Posterior to level V
• Radiotherapy target area
• Real time quantitative PCR
• Peripheral blood
• Circulating tumor cells
• Tumor volume
• Treatment failure
• Radiation induced hypothyroidism
• Normal tissue complication probability
• Late complication
• Plasma Epstein–Barr virus
• 5 fluorouracil
• Metastatic nasopharyngeal carcinoma
• Epstein–Barr virus DNA
• Tumor response
• Local treatment
• Insulin like growth factor binding protein 1
• Insulin like growth factor 1
• Clinical prognosis
• Gene amplification
• Head neck cancer
• Distinguishable geographic
• Racial distribution worldwide
• Organs at risk
• Chemo radiotherapy
• Prospective clinical trials
• Accurate basis
• Diagnostic value
• Cathepsin B
• Cathepsin D
• Neoadjuvant chemotherapy
• Surrogate endpoint
• Overall survival